F. Ye

发表

S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials

H. An, Jingxun Wu, Zhenkui Pan, 2014, Tumor Biology.

Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases.

B. Li, Yanming Zhou, Lupeng Wu, 2013, World journal of gastroenterology.

Short- and long-term outcomes after enucleation of pancreatic tumors: An evidence-based assessment.

Yanming Zhou, Lupeng Wu, Min Zhao, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Survival after Gastrectomy in Node-Negative Gastric Cancer: A Review and Meta-Analysis of Prognostic Factors

Yanming Zhou, Yumin Li, Lupeng Wu, 2015, Medical science monitor : international medical journal of experimental and clinical research.

Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis

Jingxun Wu, F. Ye, Jiani Zheng, 2020, PloS one.

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.

D. Ferry, Baolan Li, Shun Lu, 2022, The Lancet. Oncology.

KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer.

N. Xu, Yanqiao Zhang, J. Ying, 2022, European journal of cancer.

Evidence-based value of prophylactic intraperitoneal drainage following pancreatic resection: a meta-analysis.

Yanming Zhou, Lupeng Wu, Xiaofeng Zhang, 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Ef ﬁ cacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial

Lei Wang, Xueqin Chen, Wei Li, 2022 .

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases

B. Jiang, Jingxun Wu, Weixi Guo, 2022, Frontiers in Oncology.

Adjuvant Intrahepatic Injection Iodine-131-Lipiodol Improves Prognosis of Patients with Hepatocellular Carcinoma After Resection: a Meta-Analysis

Yanming Zhou, Lupeng Wu, Ye Hong, 2015, Indian Journal of Surgery.

Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma

Yanming Zhou, Le-hua Shi, Lupeng Wu, 2013, BMC Gastroenterology.

Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

Yang Zhang, Changli Wang, Wen-Wei Hu, 2022, Cancer communications.

Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: a systematic review and a meta-analysis

Yanming Zhou, Lupeng Wu, F. Ye, 2014, BMC Surgery.

Treatment patterns and costs in cutaneous squamous cell carcinoma (CSCC) patients with nodal dissection, chemotherapy, and/or radiation therapy.

C. Schmults, Q. Harshaw, M. Fury, 2018 .

Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.

H. An, Jingxun Wu, Zhenkui Pan, 2015, Journal of thoracic disease.

Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing.

W. Feng, Xiaoqing Liu, Yunpeng Liu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The preliminary efficacy of KN026 (Anti-HER2 BsAb) in advanced gastric and gastroesophageal junction cancer patients with HER2 expression.

Jianming Xu, Yanqiao Zhang, J. Ying, 2021 .

The discordance pattern of molecular sub-types between primary and metastatic sites in Chinese breast cancer patients.

X. Zhang, Hongxia Wang, Rongxuan Zhu, 2018, International journal of clinical and experimental pathology.

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.

W. Feng, Xiaoqing Liu, Yunpeng Liu, 2019, The Lancet. Respiratory medicine.

EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials

Hua Wu, Qing-Xia Zhou, Long Sun, 2018, OncoTargets and therapy.

First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.

Ying Cheng, L. Shen, S. Qin, 2021 .

Efficacy and safety of SH-1028 in patients with EGFR T790M positive non-small-cell lung cancer: a multicenter, single-arm, open-label, phase 2 trial.

Xueqin Chen, L. Xing, S. Ren, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC).

Yanqiao Zhang, J. Ying, N. Xu, 2022, Journal of Clinical Oncology.

MA14.05 A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)

Ying Cheng, C. Bai, Jin-Ji Yang, 2019, Journal of Thoracic Oncology.

Metastatic sites and lesion numbers cooperated to predict efficacy of PD‐1 inhibitor‐based combination therapy for patients with metastatic colorectal cancer

W. Zhong, Xile Zhou, Yinjun He, 2023, Cancer medicine.

The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.

J. Lai, Tianwen Xu, Zhiyong He, 2021 .

A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.

Ying Cheng, Jin-Ji Yang, C. Bai, 2020, Lung cancer.

Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).

Y. Ba, S. Qin, Likun Liu, 2018 .

Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.

Y. Ba, S. Qin, Likun Liu, 2018 .

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.

Baolan Li, Shun Lu, C. Ding, 2023, The Lancet. Respiratory medicine.

EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials

Hua Wu, Qing-Xia Zhou, Long Sun, 2018, OncoTargets and therapy.

egFr-TKi-based vs non-egFr-TKi-based adjuvant therapy in resected non-small-cell lung cancer with egFr mutations: a meta-analysis of randomized controlled trials

Long Sun, Jingxun Wu, F. Ye, 2018 .

egFr-TKi-based vs non-egFr-TKi-based adjuvant therapy in resected non-small-cell lung cancer with egFr mutations: a meta-analysis of randomized controlled trials

Long Sun, Jingxun Wu, F. Ye, 2018 .

Short- and long-term outcomes after enucleation of pancreatic tumors: An evidence-based assessment.

Yanming Zhou, Lupeng Wu, Min Zhao, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study

Y. Cheng, S. Cang, C. Ding, 2022, Annals of Oncology.

Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?

Y. Ba, M. Tao, S. Qin, 2018 .